Dolastatin-10 in metastatic melanoma: A phase II and pharmokinetic trial of the California Cancer Consortium

Investigational New Drugs

Volumn 19, Issue 4, 2001, Pages 335-340

  Margolin, Kim ^a   Longmate, Jeffrey ^a   Synold, Timothy W ^a   Gandara, David R ^b   Weber, Jeffrey ^c   Gonzalez, Rene ^d   Johansen, Mary J ^e   Newman, Robert ^e   Baratta, Tracey ^a   Doroshow, James H ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Dolastatin 10; Metastatic melanoma; Pharmokinetics

Indexed keywords

DOLASTATIN 10; PENTAPEPTIDE;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CENTER; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG ISOLATION; FEMALE; HUMAN; MALE; MELANOMA; MICROTUBULE ASSEMBLY; MOLLUSC; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STEADY STATE; TREATMENT OUTCOME;

EID: 0034851434     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1010626230081     Document Type: Article

References (36)

1. Adjuvant therapy for the treatment of high risk for recurrent stage II and III disease
2. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma
3. Phase II study of BCNU, DTIC, cisplatin and tamoxifen in advanced melanoma: A Southwest Oncology Group study
4. Phase III trial of Melacine® melanoma theraccine versus combination chemotherapy in the treatment of stage IV melanoma
5. Multi-institutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma
6. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma
7. Sequential chemoimmunotherapy with cisplatin, interleukin-2 and interferon alfa-2a for metastatic melanoma
8. Combination chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma
9. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: A randomized trial of the European Organization for the Research and Treatment of Cancer Melanoma Cooperative Group
10. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b
11. The isolation and structure of a remarkable marine animal antineoplastic constituent: Dolastatin-10
12. Effects of dolastatins on human B-lymphocytic leukemia cell lines
13. Dolastatin-10 and dolastatin 15: Effects of two natural peptides on growth and differentiation of leukemia cells
14. Cytotoxic effects of Dolastatin-10 and 15 on human leukemia cell lines
15. Bcl-2: An antidote to programmed cell death
16. Activity of Dolastatin-10 against small cell lung cancer in vitro and in vivo: Induction of apoptosis and bcl-2 modification
17. Inactivation of bcl-2 by phosphorylation
18. Taxol-induced apoptosis and phosphorylation of bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway
19. Identification of a p53-dependent negative response element in the bcl-2 gene
20. Role of Peglacoprotein in Dolastatin-10 resistance
21. Identification of the multidrug-resistance protein (MRP) as the glutathione-s-conjugate export pump of erythrocytes
22. A phase I pharmokinetic/pharmacodynamic study of Dolastatin-10 in adult patients with advanced solid tumors
23. Phase I trial of Dolastatin-10 (NSC 376128) in patients with advanced solid tumors
24. Quantitation of Dolastatin-10 using HPLC/electrospray ionization mass spectrometry: Application in a phase I clinical trial
25. Application of Akaike's information criterion in the evaluation of linear pharmacokinetic equations
26. p53 mutations in human cancers
27. WAF1, a potential mediator of p53 tumor suppression
28. Immunohistochemical detection of p53 in melanomas with rare p53 gene mutations is associated with mdm-2 overexpression
29. p53 expression is rare in cutaneous melanomas
30. Overexpression and mutations of p53 in metastatic malignant melanomas
31. p53 gene mutation and expression in naevi and melanomas
32. ImmunohistochemicaI analysis of the N-ras p21 and the p53 proteins in naevi, primary tumours and metastases of human cutaneous malignant melanoma: Increased immunopositivity in hereditary melanoma
33. Toxicity of Dolastatin-10 in mice, rats and dogs and its clinical relevance
34. Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain
35. Growth inhibition of human lymphoma cell lines by the marine products, dolastatins 10 and 15
36. Novel marine-derived anticancer agents: A phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors